Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis

被引：0
|
作者：
Esser, S. [1 ]
Stellbrink, H-J [2 ]
Heiken, H. [3 ]
Meynard, J-L [4 ]
Thorpe, D. [5 ]
Schreiber, S. [6 ]
Heinzkill, M. [6 ]
Sahali, S. [7 ]
Ramroth, H. [5 ]
Haubrich, R. [8 ]
机构：
[1] Univ Hosp Essen, Dept Venerol, Essen, Germany
[2] ICH Study Ctr, Hamburg, Germany
[3] Praxis Dres Kuhlmann Holm Heiken, Hannover, Germany
[4] Hop St Antoine, Paris, France
[5] Gilead Sci Europe Ltd, Uxbridge, Middx, England
[6] Gilead Sci GmbH, Munich, Germany
[7] Gilead Sci, Paris, France
[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/30
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [1] Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF)
    Goorney, B.
    Perez, K.
    HIV MEDICINE, 2019, 20 : 39 - 39
  • [2] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [3] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice-6 months results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H-J
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Heinzkill, M.
    HIV MEDICINE, 2019, 20 : 61 - 61
  • [4] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adult patients living with HIV-1 in routine clinical practice: 6-month results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H. J.
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Robinson, C.
    Heinzkill, M.
    HIV MEDICINE, 2020, 21 : 17 - 17
  • [5] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    HIV MEDICINE, 2020, 21 : 12 - 12
  • [6] DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)
    Post, F.
    Spinner, C.
    Coll, P.
    Hawkins, T.
    Anderson, J.
    Zhong, L.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 243 - 244
  • [7] Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results
    Ruane, P. J.
    Clarke, A.
    Post, F. A.
    Schembri, G.
    Jessen, H.
    Trottier, B.
    Bergin, C.
    Molina, J-M
    Wong, P.
    Ebrahimi, R.
    Brainard, D. M.
    Osinusi, A.
    Das, M.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 95 - 96
  • [8] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent
    Post, Frank
    Yazdanpanah, Yazdan
    Schembri, Gabriel
    Lazzarin, Adriano
    Reynes, Jacques
    Maggiolo, Franco
    Yan, Mingjin
    Abram, Michael
    Tran-Muchowski, Cecilia
    Cheng, Andrew
    Rhee, Martin
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [9] Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV-suppressed patients
    Cicalini, S.
    Lorenzini, P.
    Grilli, E.
    Plazzi, M. M.
    De Zottis, F.
    Camici, M.
    Fusto, M.
    Gagliardini, R.
    Bellagamba, R.
    Antinori, A.
    HIV MEDICINE, 2021, 22 : 31 - 32
  • [10] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F
    Acosta, R.
    Andreatta, K.
    D'Antoni, M.
    Collins, S.
    Martin, H.
    White, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 106 - 106
12345